ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,093Medicare Part D Prescriptions Filled, Including Refills

Rank: 143 out of 761

$464K Total Retail Price of All Prescriptions

Rank: 150 out of 761

580 Patients Receiving at Least One Drug in Part D
82%Patients 65 Years and Older
40% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Oregon
Lower avg

Schedule Two
Controlled Substances

4% of this provider’s 580 patients filled at least one prescription for a schedule two drug, compared to an average of 9%.

Schedule Three
Controlled Substances

12% of this provider’s 580 patients filled at least one prescription for a schedule three drug, compared to an average of 13%.

Risky Drugs to Seniors

0% of this provider’s 7,618 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

24% of this provider’s prescriptions were for brand-name drugs, compared to an average of 23%.

Prescription Price

$51 was the average price of a prescription from this provider, compared to $54 among peers.

Prescriptions per Patient

16 is the average number of prescriptions (including refills) per patient, compared to an average of 17.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Oregon
SIMVASTATIN 544 464 1 2
AMLODIPINE BESYLATE 478 434 2 6
LISINOPRIL 456 378 3 1
LEVOTHYROXINE SODIUM 308 274 4 3
OMEPRAZOLE 290 211 5 4
METFORMIN HCL 210 171 6 10
HYDROCODONE-ACETAMINOPHEN 198 161 S3 7 5
LOSARTAN POTASSIUM 188 187 8 13
FUROSEMIDE 182 154 9 7
METOPROLOL TARTRATE 180 161 10 14
HYDROCHLOROTHIAZIDE 154 115 11 11
ATORVASTATIN CALCIUM 149 127 12 12
GLIMEPIRIDE 148 137 13 48
WARFARIN SODIUM 129 127 14 9
CITALOPRAM HBR 128 114 15 19
ALENDRONATE SODIUM 123 115 16 21
DONEPEZIL HCL 121 121 17 33
DOXAZOSIN MESYLATE 115 84 18 55
METOPROLOL SUCCINATE 91 74 19 16
LOVASTATIN 90 83 20 17
FINASTERIDE 90 68 20 73
CARVEDILOL 90 90 20 26
ALLOPURINOL 89 89 23 28
ATENOLOL 84 74 24 8
TAMSULOSIN HCL 78 72 25 27
CYMBALTA 76 76 26 53
PROPRANOLOL HCL 75 62 27 100
GABAPENTIN 74 42 28 15
MIRTAZAPINE 65 65 29 50
NAPROXEN 63 60 30 105
TRIAMCINOLONE ACETONIDE 62 50 31 84
POTASSIUM CHLORIDE 62 51 31 18
PANTOPRAZOLE SODIUM 59 58 33 40
ISOSORBIDE MONONITRATE ER 58 46 34 72
CRESTOR 58 50 34 36
SERTRALINE HCL 58 43 34 25
CIPROFLOXACIN HCL 56 47 37 63
NAMENDA 55 55 38 59
DIOVAN 54 49 39 58
FLUTICASONE PROPIONATE 53 34 40 29
MICARDIS 53 53 40 161
PROAIR HFA 53 32 40 32
BUSPIRONE HCL 53 37 40 154
SPIRONOLACTONE 52 43 44 45
CELEBREX 50 40 45 125
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Feb. 8, 2013.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.